Last 25 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -4.37 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 221.74 | — | 50.39 | 45.66 | 60.80 | 75.62 | 76.70 | 61.81 | 15.35 | 7.15 | 5.66 | 6.43 | — |
| — | — | -34.3% | -26.1% | +296.2% | +958.3% | +1255.5% | +861.5% | — | — | — | — | — | |
| P/B Ratio | 7.08 | 3.90 | 3.01 | 1.74 | 3.68 | 4.10 | 2.86 | 0.89 | 1.96 | 16.77 | 10.33 | 4.39 | 1.61 |
| — | -4.7% | +5.2% | +95.3% | +87.6% | -75.6% | -72.3% | -79.7% | +21.7% | +618.9% | +703.6% | +141.2% | -49.9% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | 0.63 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | — | 82.1% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 95.3% | -34.1% | -65.5% | — |
| — | — | -17.9% | 0.0% | 0.0% | +4.9% | +393.4% | +252.6% | — | — | — | — | — | |
| Operating Margin | -3382.4% | — | -1157.6% | -1525.5% | -3030.3% | -1736.2% | -1692.4% | -12857.0% | -2473.9% | -130.0% | -135.4% | -189.1% | — |
| — | — | +31.6% | +88.1% | -22.5% | -1235.9% | -1149.8% | -6698.0% | — | — | — | — | — | |
| Net Margin | -3240.4% | — | -1080.9% | -1423.1% | -2930.9% | -1618.6% | -1528.0% | -12584.3% | -2421.2% | -121.9% | -130.4% | -180.6% | — |
| — | — | +29.3% | +88.7% | -21.1% | -1228.0% | -1072.2% | -6867.0% | — | — | — | — | — |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -194.6% | -21.6% | -15.1% | -17.1% | -40.5% | -20.1% | -13.4% | -63.9% | -147.1% | -56.4% | -47.9% | -28.0% | -39.2% |
| — | -7.2% | -12.4% | +73.3% | +72.4% | +64.4% | +72.0% | -128.2% | -275.3% | -76.3% | -82.9% | -3.3% | -157.0% | |
| ROA | -150.7% | -19.3% | -13.6% | -14.3% | -32.3% | -17.0% | -11.7% | -55.3% | -76.7% | -6.5% | -12.4% | -11.8% | -28.5% |
| — | -13.3% | -15.8% | +74.2% | +57.9% | -163.8% | +5.5% | -367.3% | -168.7% | +73.7% | +39.7% | +46.3% | -118.8% | |
| ROIC | -700.3% | -72.3% | -37.9% | -69.1% | -118.9% | -49.4% | -55.2% | -492.1% | — | — | — | — | — |
| — | -46.2% | +31.3% | +86.0% | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 44.2% YoY to 8.90x, strengthening the short-term liquidity position.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.02 | 0.02 | 0.02 | 0.03 | 0.01 | 0.01 | 0.01 | 0.01 | 0.06 | 0.05 | 0.02 | 0.02 |
| — | +20.1% | +40.9% | +173.0% | +93.8% | -79.3% | -79.1% | -66.6% | -21.2% | +666.0% | +734.5% | +210.0% | +165.6% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 4.08 | 8.90 | 12.13 | 10.49 | 4.08 | 6.17 | 7.12 | 10.18 | 6.63 | 3.96 | 1.50 | 1.87 | 3.09 |
| — | +44.2% | +70.2% | +3.0% | -38.5% | +56.1% | +375.7% | +443.4% | +114.6% | -0.3% | -65.7% | -60.7% | -46.9% | |
| Quick Ratio | 4.08 | 8.90 | 12.13 | 10.49 | 4.08 | 6.17 | 7.12 | 10.18 | 6.63 | 3.96 | 1.51 | 1.91 | 3.09 |
| — | +44.2% | +70.2% | +3.0% | -38.5% | +56.1% | +373.2% | +434.0% | +114.6% | -0.3% | -65.5% | -60.0% | -46.9% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 25 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonImmunome, Inc.'s current P/E is -4.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Immunome, Inc.'s current operating margin is -3382.4%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Immunome, Inc.'s business trajectory between earnings reports.